Advertisement

Picture EBD Group BioPharm America 2021 Digital BPA2021 650x80
Organisation › Details

Genovis (Group)

Genovis’ business concept is to apply its knowledge and imagination to design and provide innovative tools for development of the drugs of the future. Today Genovis sells several enzyme products known as SmartEnzymes™ all over the world in innovative product formats that facilitate development and quality control of biological drugs. The Group consists of Genovis AB and the wholly owned subsidiary Genovis Inc. (US). Genovis’ shares are listed on NASDAQ First North Stockholm and Erik Penser Bank is the Company’s Certified Adviser. *

 

Period Start 2009-01-22 existent
  Today Genovis AB
Products Industry industrial enzyme
  Industry 2 transfection reagents
Persons Person Olsson, Fredrik (Genovis 201906 CEO)
  Person 2 Humaloja, Johny (Genovis 201908– CFO before Biogen + Boston Scientific)
     
Region Region Lund
  Country Sweden
  Street 2 Scheelevägen
Medicon Village
  City 220 07 Lund
  Tel +46-46-101230
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
  Currency SEK
  Annual sales 61,029,721 (net sales, consolidated (2020) 2020-12-31)
  Profit 6,445,902 (2020-12-31)
  Cash 44,117,801 (2020-12-31)
     
    * Document for �About Section�: Genovis AB. (6/19/19). "Press Release: Genovis AB Hires CFO".
     
   
Record changed: 2021-04-28

Advertisement

Picture EBD Group Connector Personal Networking in Life Sciences 650x80

More documents for Genovis (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Demy-Colton BioFuture 2021 NYC A October 650x80px




» top